Specificity |
This ELISA kit shows no cross-reactivity with any of the cytokines tested (e.g., human ANG, CD23, Eotaxin, GCSF, GM-CSF, GRO- alpha, GRO-beta, GRO-gamma, I-309, IFN-gamma, IL-1alpha, IL-1beta, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 (p40), IL-12 (p70), IL-15, IL-16, IP-10, MCP-1, MCP-2, MCP-3, MCP-4, MCSF, MIG, MIP-1alpha, MIP-1beta, NAP-2, PDGF, PF-4, PARC, SCF, SDF-1alpha, TNFbeta, TGFbeta1, TGFbeta2, TGFbeta3, VEGF). |
Citation |
1. Steed D, Trumpower C, Duffy D, Smith C, Marshall V, et al. Amnion-derived Cellular Cytokine Solution A Physiological Combination of Cytokines for Wound Healing. Eplasty. 2008, 8:e18. 2. Hampel U, Klonisch T, Sel S, et al. Insulin-like Factor 3 Promotes Wound Healing at the Ocular Surface. Endocrinology. 2013, 154(6):2034–2045. 3. Kralisch S, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M. Tissue inhibitor of metalloproteinase 1 expression and secretion are induced by beta-adrenergic stimulation in 3T3-L1 adipocytes. J Endocrinol. 2006, 189:665-670. 4. Upadhyay A, Sharma G, Kivivuori S, Raye W S, Zabihi E, et al. Role of a LIF antagonist in LIF and OSM induced MMP-1, MMP-3, and TIMP-1 expression by primary articular chondrocytes. Cytokine. 2009, 46:332–338. 5. Fernandez-Yunquera A., et al. Everolimus immunosuppression reduces the serum expression of fibrosis markers in liver transplant recipients. World J Transplant 2014, 4(2): 133-140. http://dx.doi.org/10.5500/wjt.v4.i2.133 6. Kilic Z., et al. Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases levels in pediatric patients with congenital heart disease: Relationship to cardiac functions. Anatolian J of Card. Published ahead of print, June 25th 2014. DOI:10.5152/akd.2014.4950 7. Esa S., et al. Study of the level of sputum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor metalloproteinase-1 (TIMP-1) in COPD patients. Egyptian Journal of Chest Diseases and Tuberculosis Available online 18 July 2014 DOI: 10.1016/j.ejcdt.2014.06.014 8. Ghodpage P., et al. Influence of phase I periodontal therapy on levels of matrix metalloproteinase 1 and tissue inhibitor of metalloproteinase 1 . The Saudi Dental Journal. Available online 15 July 2014 DOI: 10.1016/j.sdentj.2014.05.003 9. Acar B., Nese, Z., et al. Serum MMP-2, MMP-9, TIMP-1 and TIMP-2 levels in multiple sclerosis clinical subtypes and their diagnostic value in the progressive disease course. Biomedical Research, Volume 25, Issue 3, Pages 343 - 350. 2014. 10. Gluba-Brzozka A., et al. Markers of increased cardiovascular risk in patients with chronic kidney disease. Lipids in Health and Disease 2014, 13:135 doi:10.1186/1476-511X-13-135 11. Koob T., et al. Cytokines in single layer amnion allografts compared to multilayer amnion/chorion allografts for wound healing. Journal of Biomedical Materials Research Part B: Applied Biomaterials. Aug 2014, epub ahead of print. DOI: 10.1002/jbm.b.33265 12. Kiliç Z., et al. Circulating matrix metalloproteinases and tissue inhibitors of metalloproteinases levels in pediatric patients with congenital heart disease: Relationship to cardiac functions. Anadolu Kardiyol Derg 2014, 14: 531-41. DOI:10.5152/akd.2014.4950 13. Rolin G., et al. In vitro study of the impact of mechanical tension on the dermal fibroblast henotype in the context of skin wound healing. Journal of Biomechanics Sept 2014, epub ahead of print. http://dx.doi.org/10.1016/j.jbiomech.2014.07.015 |